STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Clinical trials for STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests drug combo in fight against advanced head and neck cancer
Disease control OngoingThis large, late-stage trial is testing whether adding the drug bevacizumab to standard chemotherapy helps patients with advanced head and neck cancer that has returned or spread. The study enrolled 403 participants to see if the combination helps people live longer or slows canc…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Head-to-Head cancer radiation trial: protons vs. photons
Disease control OngoingThis study aims to find out if a newer type of radiation called proton beam therapy is better than standard photon therapy for treating throat cancer. It will compare how well each treatment controls the cancer and, importantly, which one causes fewer severe side effects. About 4…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo tested to fight tough head and neck cancers
Disease control OngoingThis study is testing whether combining two existing drugs, pembrolizumab and cabozantinib, can help control advanced head and neck cancer that has come back or spread. It will involve about 36 patients whose cancer cannot be removed by surgery. The main goal is to see how many p…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo attack on HPV throat cancer: can we boost the immune system to fight tumors?
Disease control OngoingThis study is testing a new combination treatment for people with a specific type of advanced throat cancer caused by HPV. It combines two immunotherapy drugs (nivolumab and ipilimumab) that help the body's immune system fight cancer, along with a targeted, lower-dose radiation t…
Matched conditions: STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC